Josep Monserrat
About Josep Monserrat
Josep Monserrat is a Senior Scientist at BenevolentAI with extensive experience in oncology and cancer biology, having previously worked at The Francis Crick Institute and University College London.
Current Role at BenevolentAI
Josep Monserrat holds the position of Senior Scientist at BenevolentAI. In his role, he collaborates with pharmaceutical companies on cancer drug development projects. His contributions involve leveraging artificial intelligence to advance the understanding and treatment of cancer.
Experience at The Francis Crick Institute
Josep Monserrat's tenure at The Francis Crick Institute included two significant roles. From 2019 to 2020, he worked as a Postdoctoral Researcher, contributing to research that explored the molecular mechanisms of cancer. He also spent five years as a PhD Student from 2014 to 2019, undertaking a project that was a collaborative effort between The Francis Crick Institute and University College London. During his time there, he mentored undergraduate students and developed a novel assay for detecting cancer biomarkers.
Educational Background
Josep Monserrat completed his Doctor of Philosophy (PhD) in Oncology and Cancer Biology at University College London (UCL) from 2014 to 2019. Prior to that, he earned a Bachelor's Degree in Biochemistry from UCL, studying from 2010 to 2014. His early education culminated in achieving Batxiller from I.E.S. Felanitx, where he studied from 2004 to 2010.
Previous Research Experience
Before his roles at The Francis Crick Institute, Josep Monserrat gained research and industry experience through various positions. He completed a Final Year Project in Biochemistry at University College London in 2014, participated in a Summer School at the University of Zurich in 2013, and undertook an Industrial Placement at Eli Lilly and Company from 2012 to 2013. Additionally, he completed a Summer Internship at the University of Cambridge in 2011.
Research Contributions and Publications
Josep Monserrat has made significant contributions to the field of oncology and cancer biology through his research. He has published multiple papers in peer-reviewed journals and presented his findings at international conferences, including the European Association for Cancer Research (EACR) annual meeting. His work has been supported by a research grant from a notable cancer research foundation.